Angioedema News

January 15, 2021January 15, 2021

COVID-19 Inflammation May Result in Angioedema Symptoms, Case Report Finds

A case report describes a man with confirmed COVID-19 who developed acute angioedema — a skin symptom that had not previously been associated with the virus — in his lips. “To ... Read more

January 8, 2021January 8, 2021

What Do Most HAE Patients Want From Treatment? Fewer Attacks, Survey Finds

Angioedema News

The vast majority of people with hereditary angioedema (HAE) stress the importance of their preventative therapy correcting C1 inhibitor protein deficiency, allowing for fewer attacks, as the leading factor in ... Read more

January 4, 2021January 5, 2021

3 Methods for Measuring C1-INH Activity Give Comparable Results

Angioedema News

Assessing C1-inhibitor (C1-INH) activity for the diagnosis and monitoring of hereditary angioedema (HAE) can be done through three distinct validated methods with similar accuracy, a new study found. The study, ... Read more

December 21, 2020December 21, 2020

New Ruconest Manufacturing Facility Will Be Built in 2021

Angioedema News

Pharming Group has committed to building a new manufacturing facility in the Netherlands to expand production of Ruconest (conestat alfa), its treatment for acute attacks of hereditary angioedema (HAE). Construction will ... Read more

December 18, 2020December 18, 2020

Just-approved Orladeyo Now Being Shipped to US Patients

Angioedema News

Just a couple of weeks after its U.S. approval, Orladeyo (berotralstat) is now available for direct shipment to hereditary angioedema (HAE) patients in the United States who hold a prescription for ... Read more

December 14, 2020December 14, 2020

Takhzyro Approved in China for Routine Prevention of HAE Attacks

Angioedema News

Takeda’s Takhzyro (lanadelumab) has been approved in China for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, the company announced. It now becomes the ... Read more

December 11, 2020December 11, 2020

Oral PHA121 May Be Better On-demand HAE Treatment Than Firazyr, Early Data Show

Angioedema News

PHA121 (PHA-022121), Pharvaris‘ oral therapy for hereditary angioedema (HAE), outperformed Firazyr (icatibant acetate) — an approved therapy with a similar mechanism of action — in a small study of healthy ... Read more

December 7, 2020December 8, 2020

FDA Approves Orladeyo, 1st Oral Treatment to Prevent HAE Attacks

Angioedema News

The U.S. Food and Drug Administration has approved Orladeyo (berotralstat) as an oral treatment to prevent swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. This approval ... Read more

December 4, 2020December 4, 2020

New Generic Version of Firazyr Now Available in US to Treat Acute HAE Attacks

Angioedema News

Icatibant injection, a generic form of Firazyr from Fresenius Kabi, is now available to adults in the United States for the treatment of acute attacks of hereditary angioedema (HAE), the ... Read more

December 3, 2020December 4, 2020

NORD Push for Rare Disease Advisory Councils Focus of Dec. 16 Public Meeting

Angioedema News

To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders (NORD) ... Read more

November 30, 2020November 30, 2020

Injectable Preventive Treatments Weigh on Patients and Caregivers, Surveys Show

Angioedema News

Routine injectable treatments to prevent hereditary angioedema (HAE) attacks place a large burden on patients and their caregivers, a survey study has found. Surveyed patients and doctors also agreed that ... Read more

November 23, 2020November 24, 2020

Takhzyro Safely Prevents HAE Attacks Over Long Term, Extension Study Shows

Angioedema News

Takeda’s Takhzyro (lanadelumab) continues to safely prevent and reduce the frequency of swelling attacks in people with hereditary angioedema (HAE), according to 2.5 years of data from the HELP open-label ... Read more

November 20, 2020December 25, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

Angioedema News, COVID-19 News

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a ... Read more

November 18, 2020December 20, 2020

Latest NORD Webinar Offers Insights on Starting Nonprofit, Patient Registry

Angioedema News

Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and patient registry. They shared about how ... Read more

November 13, 2020November 13, 2020

Takhzyro, for HAE Attacks, Moves Closer to Public Funding Across Canada

Angioedema News

Takeda Canada announced reaching an agreement for public funding in Canada of Takhzyro (lanadelumab), its treatment for eligible hereditary angioedema (HAE) patients. The agreement was reached between the company and the ... Read more